CohBar, Inc. (CWBR) and Morphogenesis, Inc., a privately-held Phase 2/3 clinical-stage biotechnology company developing personalized cancer vaccines and tumor microenvironment modulators to overcome resistance to current immunotherapies, have entered into a definitive agreement for an all-stock merger.